Abstract
Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Keywords: Electrochemotherapy, Electropermeabilization, Cisplatin, Bleomycin, clinical trials, subcutaneaous tumors, electrotransfer, immune-stimulating genes, electro-photodynamic therapy, cancer
Current Pharmaceutical Design
Title:Electrochemotherapy: Progress and Prospects
Volume: 18 Issue: 23
Author(s): Jean-Michel Escoffre and Marie-Pierre Rols
Affiliation:
Keywords: Electrochemotherapy, Electropermeabilization, Cisplatin, Bleomycin, clinical trials, subcutaneaous tumors, electrotransfer, immune-stimulating genes, electro-photodynamic therapy, cancer
Abstract: Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
Export Options
About this article
Cite this article as:
Escoffre Jean-Michel and Rols Marie-Pierre, Electrochemotherapy: Progress and Prospects, Current Pharmaceutical Design 2012; 18 (23) . https://dx.doi.org/10.2174/138161212801227087
DOI https://dx.doi.org/10.2174/138161212801227087 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinically Relevant Reprogramming to Pluripotency
Recent Patents on Regenerative Medicine Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery Functional Genomics: New Insights into the Function of Low Levels of Gene Expression in Stem Cells
Current Genomics Dietary Polyphenols and Type 2 Diabetes: Current Insights and Future Perspectives
Current Medicinal Chemistry 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Expression of mTOR/70S6K Signaling Pathway in Melanoma Cancer Cells and the Effects of Dacarbazine and Metformin
Current Cancer Therapy Reviews Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Natural Products as Modulators of Spermatogenesis: The Search for a Male Contraceptive
Current Molecular Pharmacology Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Diagnosis and Possible Use of Traditional Medicinal Plant to combat COVID-19
Coronaviruses Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Role of the Peroxynitrite - Poly (ADP-Ribose) Polymerase Pathway in the Pathogenesis of Liver Injury
Current Pharmaceutical Design Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole
Current Drug Metabolism Reviewing Antiviral Research against Viruses Causing Human Diseases - a Structure-Guided Approach
Current Molecular Pharmacology